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CC BY-NC-ND license (http://creativeAbstract Objective: To assess the effectiveness and safety of electroacupuncture for the
treatment of diabetic peripheral neuropathy (DPN). Clinical studies in China have shown the
beneficial effect of electroacupuncture compared with conventional medicine. However,
the effectiveness of electroacupuncture has not been well acknowledged internationally.
Methods: We searched the following databases from their inception through February 2016:
MEDLINE, the Cochrane Central Register of Controlled Trials (April, 2015), SinoMed, China Na-
tional Knowledge Infrastructure, VIP, Wanfang Database, Chinese Important Conference Pa-
pers Database, and the Chinese Dissertation Database. Randomized controlled trials (RCTs)
were included if they compared electroacupuncture to conventional medicine, placebo, or
no treatment on DPN patients. RevMan 5.3 software was used for data analysis, with effect es-
timate presented as relative risk (RR) and mean difference (MD) with a 95% confidence interval
(CI).
Results: Eleven RCTs involving 837 participants were included. The methodological quality of
included RCTs was generally poor in terms of sequence generation, allocation concealment,
blinding, incomplete outcome data, and selective outcome reporting. Meta-analysis showed
that electroacupuncture had a better effect on global symptom improvement than methylco-
balamin (RR Z 1.29; 95% CI: 1.14e1.46) and vitamin B (RR Z 1.60; 95% CI: 1.33e1.94). Only
two RCTs reported adverse events.0 64286757.
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10 W. Xiong et al.Conclusions: Because of the high risk of bias of included trials, we cannot make a conclusion on
the effectiveness of electroacupuncture for DPN. More rigorously designed and conducted
multicenter double-blind RCTs are needed to support the use of electroacupuncture for DPN.
ª 2016 Beijing University of Chinese Medicine. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Introduction
Diabetes mellitus is the seventh leading cause of death
worldwide, causing 1.4 million deaths in 2011 (about 2.6%
of total global deaths for that year).1 Diabetic peripheral
neuropathy (DPN) is one of the most common chronic
complications of diabetes mellitus, and is among the main
causes of disability.2 Studies in America have shown that
32.7% of people with diabetes mellitus3 have evidence of
DPN and multicenter studies in Europe have shown that 28%
of people with diabetes mellitus have evidence of DPN.4
The incidence of DPN in worldwide diabetic patients
ranges from 5% to 80%, and is still increasing.5
DPN involves sensory, motor, and autonomic nerve le-
sions, with sensory neuropathy most frequently experi-
enced.6 The principle clinical features of DPN are
progressive loss of sensation and movement in the distal
limbs, manifesting as intense limb numbness, severe pain,
muscle weakness and atrophy, and weakening or complete
loss of tendon reflexes, ultimately leading to foot ulcers,
gangrene, and even amputation.7,8 These symptoms result
in a huge disease burden in terms of disability and depletion
of health care resources.9e11
The etiology and pathogenesis of DPN have not been
fully elucidated. For this reason, ideal drugs have still
not been developed.12 Glycemic control is fundamental
in the prevention and treatment of DPN. Medical thera-
pies that are part of the DPN drug arsenal include
methylcobalamin (vitamin B12) l to repair nerves, thioctic
acid (alpha-lipoic acid) for oxidative stress, prosta-
glandin E2 to improve microcirculation, aldose reductase
inhibitors, such as epalrestat to attenuate morphologic
abnormality of the nerves. For symptomatic treatment
with anticonvulsants, antidepressants and acesodyne are
also used for DPN.13e16 Existing pharmaceutical drugs
usually have side effects and are costly. Thus, the overall
financial burden of DPN and its complications has been
estimated at more than four billion USD in one year in
America alone.17 Therefore, better therapy options for
DPN are needed.
DPN has been treated using acupuncture for 2000
years.18 There are many types of acupuncture used in
China, including auricular, manual, scalp, electro-
acupuncture, needle tapping, acupoint injection, blood
pricking, warm needling, and moxibustion. Electro-
acupuncture is one of the most widely applied therapies for
DPN to ameliorate symptoms, improve quality of life (QoL),
and prevent other complications. In recent years, many
clinical trials and animal experiments have shown the
benefit of electroacupuncture in the treatment of
DPN.19e26Electroacupuncture for DPN is based on the theory of
traditional Chinese medicine (TCM), in which DPN is due
to decreases in the body of the fundamental substances
of yin and essence, which lead to endogenous dryness
that eventually damages the qi and yin. Because of the
interdependence of yin and yang, impairment of yin
affects yang, and results in deficiency of both yin and
yang.27 Deficiency of yin and the resulting dry-heat will
dry the body fluids, allowing pathogenic qi to enter the
channels. These two conditions can lead to the stasis of
blood and stagnation in the channels such that yang qi
cannot reach the ends of the four limbs. The sinews and
vessels lack the nourishment provided by qi and blood,
which eventually results in DPN.28e30 As DPN is caused
by qi and yin deficiency, blood stasis, and stagnation,
the treatment principle involves replenishing qi and
nourishing yin, dissolving stasis and unblocking the
channels.
This systematic review aimed to evaluate the potential
beneficial and harmful effects of electroacupuncture for
the treatment of DPN. Information from this review may
provide the foundation for formulating guidelines on elec-
troacupuncture for DPN therapy and prevention.Materials and methods
Data sources and searches
The following electronic databases were searched from
their inception through February 2016: MEDLINE (Table 1),
the Cochrane Central Register of Controlled Trials (CEN-
TRAL) (April 2015), SinoMed, Chinese Network Knowledge
Infrastructure (CNKI), Chinese Scientific Journals Database
(VIP), and Wanfang Database. The Chinese Important Con-
ference Papers Database and the Chinese Dissertation
Database were searched for gray literature.
English search terms included: “acupuncture,”
“acupuncture therapy,” “needling,” “electro-
acupuncture,” “diabetic neuropathy,” “diabetic peripheral
neuropathy,” “DPN,” “clinical trial,” and “randomized
controlled trial.” The Chinese search terms were “zhen ci,”
“zhen jiu,” “dian zhen,” “tang niao bing shen jing bing
bian,” “tang niao bing zhou wei shen jing bing bian,” “lin
chuang shi yan,” and “sui ji.” The search terms were used
individually or in combination. Reference lists of all rele-
vant studies were also hand-searched.
Two authors (WJX, XF) independently conducted the
literature search, study selection and data extraction.
Disagreement was resolved by discussion, and consensus
was reached through discussion with a third party (WC).
Table 1 MEDLINE search strategy of RCTs of electroacupuncture for treatment of diabetic peripheral neuropathy.
Strategy Search specification Articles returned
#1 (Diet, Diabetic [Mesh]) OR (Diabetic Diets) OR
(Diets, Diabetic) OR (Diabetic Diet)
15339
#2 (Peripheral Nervous System Diseases [Mesh]) OR
(Peripheral Nervous System Disease) OR (PNS Diseases)
OR (PNS Disease) OR (Peripheral Neuropathies) OR (Neuropathy,
Peripheral) OR (Peripheral Neuropathy) OR (PNS (Peripheral
Nervous System) Diseases) OR (Peripheral Nerve Diseases)
OR (Nerve Disease, Peripheral) OR (Nerve Diseases, Peripheral)
OR (Peripheral Nerve Disease) OR (Peripheral Nervous System Disorders)
154749
#3 #1 AND #2 365
#4 (Diabetic Neuropathies [Mesh]) 18395
#5 (Diabetic peripheral neuropathy) OR DPN 16554
#6 #3 OR #4 OR #5 21917
#7 (Acupuncture [Mesh]) OR (acupuncture therapy
[Mesh]) OR acupuncture OR needling OR electroacupuncture
25225
#8 Randomized controlled trial [pt] 407385
#9 Controlled clinical trial [pt] 492669
#10 Randomized [tiab] 371389
#11 Randomly [tiab] 249387
#12 Random* 1027473
#13 Placebo [tiab] 173944
#14 Trial [tiab] 423017
#15 Groups [tiab] 1581281
#16 #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 2549334
#17 Animal OR rat OR mouse OR mice OR dog OR rabbit OR duck [ti] 6106896
#18 #6 AND #7 AND #16 NOT #17 18
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Parallel randomized controlled trials (RCTs) were included
if they involved electroacupuncture for DPN, regardless of
publication status.
The definition of DPN must have met the following
diagnostic criteria: met international diabetes mellitus and
DPN criteria, such as the WHO criteria31 or the American
Diabetes Association (ADA)32; participants had predomi-
nantly distal symmetrical sensorimotor polyneuropathy of
the limbs. Other causes of multiple sensorimotor neuropa-
thy were excluded.
Our operational definition of electroacupuncture was
puncturing the body with acupuncture needles at specific
points on the corresponding channel based on TCM syn-
drome pattern differentiation and treatment, followed
by application of electric current through the
needles.33,34
The control intervention included conventional treat-
ment, sham acupuncture, placebo, or no treatment. RCTs
evaluating acupuncture therapy combined with other in-
terventions compared with those other interventions alone
were also included.
Primary outcome was global symptom improvement
measured by corroborative methods, such as the visual
analog scale or by other criteria defined by the in-
vestigators. Secondary outcomes included changes in nerve
conduction velocity measured by a corroborant instru-
mentation, QoL, health economics, and adverse events.Quality assessment
Two authors (WJX, XF) independently assessed the quality
of included RCTs according to the Cochrane risk of bias
tool.35 The following types of bias were assessed: random
sequence generation (selection bias), allocation conceal-
ment (selection bias), blinding of participants and
personnel (performance bias), blinding of outcome assess-
ment (detection bias), incomplete outcome data (attrition
bias), selective outcome reporting (reporting bias), and
baseline imbalance (other bias). Disagreement was
resolved by discussion, and consensus was reached through
discussion with a third party (WC).
Data analysis
RevMan 5.3 software was used to conduct the data analysis.
Data were presented as relative risk (RR) with 95% confi-
dence intervals (CI) for dichotomous outcomes, and mean
difference (MD) with 95% CI for continuous outcomes. Meta-
analysis was planned if the included RCTs had acceptable
homogeneity regarding study design, participants, in-
terventions, controls, and outcome measures. We tested
heterogeneity using the I2 statistic with significance set at
50%, and the chi-square statistic significance set at
P < 0.10. If we identified significant heterogeneity, the
random-effects model would be used. If we identified
enough RCTs, we planned to assess possible sources of
heterogeneity by subgroup and sensitivity analyses, and to
12 W. Xiong et al.assess the effect of small sample RCTs on results and pub-
lication bias using funnel plots.Results
Description of included studies
A total of 1306 articles were identified through primary
retrieval (Fig. 1). After reading the titles and abstracts,
1143 articles were excluded because of duplication or
inconformity of titles or abstracts. This resulted in 163 ar-
ticles for further assessment. Of these, 151 articles were
excluded because they did not meet our inclusion criteria:
inconformity of study type, participants, intervention,
control, or outcomes; lack of diagnostic criteria; andFig. 1 Flow chart ofduplicate studies. Ultimately, 12 RCTs were included,36e47
one of which was a three-armed trial.44 We determined
that the studies Li37 and Li38 reported different parts of the
same RCT, so we combined their data into 1 trial that we
referred to as Li YF 2003 (2000). Thus, 11 trials from 12
publications were included in our final analyses.
Characteristics of included RCTs are presented in
Table 2, and treatments performed are presented in
Table 3. All included RCTs were conducted and published
in China. Total number of participants was 837, with an
average of 76 participants per trial. Age of participants
ranged from 37 to 80 years. No RCT reported sample size
calculation. Treatment duration ranged from 14 days to 2
months. With respect to the diagnostic criteria of dia-
betes, 1 trial47 used the ADA guideline, 10 tri-
als36e38,40e47 used the WHO criteria, and 3 trials37e39,41selection process.
Table 2 Characteristics of included trials.
Study ID Sample size: No.(M/F) Sample age (year) Intervention Outcomes
I C I C
Li36 31 (18/13) 30 (20/10) 48 49 T: Electroacupuncture Global symptom improvement
C: Inositol
Li37,38 48 36 63.03  9.84 T: Electroacupuncture Global symptom improvement
C: Methylcobalamin MNCV in left and right median,
tibial and ulnar nerve, and SNCV
in left and right median and
sural nerve
Liu39 40 (13/27) 40 (18/22) 57.35  9.32 57.65  9.45 T: Electroacupuncture þ
methylcobalamin
Global symptom improvement
C: Methylcobalamin MNCV in common peroneal and
median nerve, SNCV in common
peroneal and median nerve
Wang40 30 (18/12) 30 (17/13) 59.20  9.56 57.90  7.29 T: Electroacupuncture Global symptom improvement
C: Methylcobalamin MNCV in common peroneal nerve
and SNCV in tibial nerve
Xue41 34 34 63.03  9.84 T: Electroacupuncture Global symptom improvement
C: Methylcobalamin MNCV and SNCV in median and
tibial nerve
Yang42 36 (20/16) 36 (19/17) NA NA T: Electroacupuncture Global symptom improvement
C: Vitamin B12 Adverse events
Ye43 30 (14/16) 36 (19/17) 61.8  9.48 58.70  8.85 T: Electroacupuncture Global symptom improvement
C: Methylcobalamin MNCV in common peroneal and
median nerve, and SNCV in median
and sural nerve




MNCV in left median, right tibial
and left ulnar nerve, SNCV in left
median, right sural and left
ulnar nerve
C: Thioctic acid injection
Zhao45 40 (22/18) 40 (20/20) 52  8 51  7 T: Electroacupuncture þ
methylcobalamin
Global symptom improvement
C: Methylcobalamin MNCV in left median, right tibial
and left ulnar nerve, SNCV in
left median, right tibial and
left ulnar nerve
Zhang46 30 (17/13) 30 (19/11) 61.8  7.8 NA T: Electroacupuncture þ
thioctic acid injection
Adverse events
C: Thioctic acid injection
Zhang47 46 (24/22) 46 (24/22) 59.1  7.4 59.5  7.2 T: Electroacupuncture Global symptom improvement
C: Vitamin B1 and B12 MNCV and SNCV in common
peroneal and median nerve
Abbreviations: C, control group; F, female; I, intervention group; M, male; MNCV, motor nerve conduction velocity; NA, not available;
SNCV, sensory nerve conduction velocity.
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nostic Criteria.48e50 Control interventions included B vi-
tamins (B1, B6, B12, and methylcobalamin), inositol, and
thioctic acid (alpha-lipoic acid) injection. No trial used
sham acupuncture, placebo, pharmaceutical drugs or no
treatment as a control. Hypoglycemic therapy, including
oral hypoglycemic agents, insulin, diabetes education,
and exercise, was used as a basic therapy in all except
one trial.47
All included trials except one46 reported global symptom
improvement and 8 trials37e41,43e45,47 reported changes inthe motor/sensory nerve conduction velocity. However, for
global symptom improvement, the classification and
demarcation points of the hierarchical outcomes of the
improvement were quite different. For the convenience of
analyzing them as dichotomous data, we merged the
“cure,” “markedly effective,” and “effective” outcomes
into a single positive category, and merged “ineffective”
outcomes into a negative category. Measurements of
changes in nerve conduction velocity were also quite
different. Only 2 trials42,46 reported adverse events, and no
trial evaluated QoL or health economics.
Table 3 Treatments in included trials.
Study ID Intervention Control
Li36 Electroacupuncture: Acupoints were BL 13 (Feishu), BL 18
(Ganshu), BL 20 (Pishu), BL 23 (Shenshu), Yishu, ST 36 (Zusanli),
SP 6 (Sanyinjiao). EA applied using continuous wave for 30 min
once daily, 10 days as 1 treatment course, total of 3 courses.
Inositol, orally, 0.5 g, TID, 10 days as 1
treatment course, 3 courses total.
Li37,38 Electroacupuncture: Primary acupoints were CV 4
(Guanyuan), CV 6 (Qihai), ST 40 (Fenglong), SP 6 (Sanyinjiao) BL
20 (Pishu), BL 23 (Shenshu), GB 30 (Huantiao), BL 58 (Feiyang).
Secondary points added based on site of neuralgia. EA applied
to acupoints at site innervated by damaged nerve using
continuous wave for 30 min, once every other day, 3 times per
week, 2 months as 1 treatment course, total of 1 course.
Methylcobalamin, orally, 500 mg, TID, 2 months
as 1 course of treatment, total of 1 course.
Liu39 Electroacupuncture D oral methylcobalamin: Acupoints
were LI 11 (Quchi), TE 5 (Waiguan), LI 4 (Hegu), ST 40
(Fenglong), GB 34 (Yanglingquan), ST 36 (Zusanli), SP 6
(Sanyinjiao), LR 3 (Taichong). EA applied using for 30 min once
daily, 10 days as 1 treatment course, total of 3 courses, with 3
days’ rest between courses. Methylcobalamin administered
same as control group.
Methylcobalamin, orally, 0.5 mg, TID, 10 days
as 1 course, 3 courses total with 3 days’ rest
between courses.
Wang40 Electroacupuncture: Acupoints were BL 20 (Pishu), BL 23
(Shenshu), GB 30 (Huantiao), GB 34 (Yanglingquan), ST 36
(Zusanli), SP 6 (Sanyinjiao), KI (Taixi), LI 11 (Quchi), TE 5
(Waiguan), LI 4 (Hegu). EA applied using dilatational wave for
30 min once daily, 6 times per week, 4 weeks as 1 treatment
course, total of 1 course.
Methylcobalamin, IM, 500 mg/mL, QD, 4 weeks
as 1 course, total of 1 course.
Xue41 Electroacupuncture: Primary acupoints were CV 12
(Zhongwan), LI 4 (Hegu), LI 11 (Quchi), PC 6 (Neiguan), ST 36
(Zusanli), ST 40 (Fenglong), SP 6 (Sanyinjiao), SP 10 (Xuehai),
Yanglingquan (GB34). Secondary points added based on site of
neuralgia. EA applied to acupoints at site innervated by
damaged nerve using continuous wave for 30 min, once daily, 5
times per week, 2 months as 1 treatment course, total of 1
course.
Methylcobalamin, orally, 500 mg, TID, 2 months
as 1 treatment course, total of 1 course.
Yang42 Electroacupuncture: Acupoints were ST 36 (Zusanli), KI 1
(Yongquan). Electrodes impregnated with herbal ingredients
(danshen) were affixed to acupoints, followed by EA at 3
wavelengths for 15 min each. Treatment was once daily, 2
weeks as 1 treatment course, total of 1 course.
Vitamin B12, IM, 500 mg/mL, QD, 2 weeks as 1
course, total of 1 course.
Ye43 Electroacupuncture: Acupoints were LI 4 (Hegu), LR 3
(Taichong) LI 11 (Quchi), KI (Taixi), ST 36 (Zusanli) KI 1
(Yongquan). EA applied using discontinuous wave for 30 min
once daily, every other day, 28 days as 1 treatment course,
total of 1 course.
Methylcobalamin, IM, 0.5 mg/mL, QD, 4 weeks
as 1 course, total of 1 course.
Zhao44 Tx group 1: Electroacupuncture; Tx group 2:
Electroacupuncture D thioctic acid IV infusion. Tx1:
Acupoints were CV 4 (Guanyuan), CV 6 (Qihai), LI 4 (Hegu), SI 3
(Houxi), KI 1 (Yongquan), ST 41 (Jiexi), SP 6 (Sanyinjiao) BL 20
(Pishu), BL 23 (Shenshu), BL 58 (Feiyang), GB 30 (Huantiao).
Secondary points added based on site of neuralgia and/or
syndrome pattern differentiation. EA applied using continuous
wave, once daily, 2 weeks as 1 treatment course, total was 2
courses, with 1 day’s rest between courses. Tx2 combined Tx1
and the control group.
Thioctic acid, IV infusion, 600 mg/250 mL over
30 min, QD, 2 weeks as 1 course, 2 courses
total.
Zhao45 Electroacupuncture D oral methylcobalamin: Acupoints
were BL 20 (Pishu), BL 23 (Shenshu), CV 6 (Qihai), CV 4
(Guanyuan), ST 36 (Zusanli), SP 6 (Sanyinjiao). Secondary
points added based on site of neuralgia and syndrome pattern
differentiation. EA applied using continuous wave for 30 min
Methylcobalamin, orally, 0.5 mg, TID, 15 days
as 1 course, 2 courses total, with 1 day’s rest
between courses.
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Table 3 (continued )
Study ID Intervention Control
once daily, 2 weeks as 1 treatment course, total was 2 courses,
with 1 day’s rest between courses. Methylcobalamin was
administered the same as the control group.
Zhang46 Electroacupuncture D thioctic acid infusion: Acupoints were
LI 15 (Jianyu), LI 11 (Quchi), PC 6 (Neiguan), LI 4 (Hegu), ST 36
(Zusanli), SP 6 (Sanyinjiao), SP 10 (Xuehai), BL 17 (Geshu), BL
40 (Weizhong), GB 34 (Yanglingquan). EA was applied with
continuous wave for 30 min, once daily, 5 times per week, 1
week as 1 course, total was 3 courses, with 2 days’ rest
between courses. Thioctic acid was administered the same as
the control group.
Thioctic acid, IV infusion, 600 mg/250 mL over
30 min, QD, 3 weeks as 1 course, total of 1
course.
Zhang47 Electroacupuncture: Acupoints were LI 4 (Hegu), LI 10
(Shousanli), LI 11 (Quchi), TE 5 (Waiguan), SP 6 (Sanyinjiao), SP
10 (Xuehai), ST 36 (Zusanli), ST 40 (Fenglong), LR 3 (Taichong)
GB 34 (Yanglingquan). EA was applied with continuous wave for
30 min once daily, 30 days as 1 treatment course, total of 1
course.
Vitamins B1 (100 mg/mL) and B12 (500 mg/mL),
both IM and QD, 30 days as 1 course, total of 1
course.
Abbreviations: BID, 2 times daily; EA, electroacupuncture; QD, once daily; TID, 3 times daily.
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Although all included trials mentioned “random alloca-
tion,” only 5 trials37e39,44e46 described the method of
random sequence generation such as using a random
number table (Figs. 2 and 3). No trial mentioned allo-
cation concealment or blinding. For incomplete outcome
data, no trial provided information on drop-outs such as
number of missing cases and the reason for the deletion.
No trial reported intention-to-treat (ITT) analysis. With
regard to selective reporting, we classified all included
trials as unclear risk of bias because the study protocols
were unattainable. No trial reported sample calculation,
and 1 RCT42 did not report whether the baseline char-
acteristics of the treatment and the control group were
comparable.Fig. 2 Risk ofEffect estimates
The effect estimates of electroacupuncture are shown in
Table 4.
Effect on global symptom improvement
Ten trials36e45,47 reported global symptom improvement
outcomes (Fig. 4). Results showed that electroacupuncture
had a better curative effect than methylcobalamin (RR
1.29; 95% CI 1.14 to 1.46) and vitamin B (RR 1.60; 95% CI
1.33 to 1.94). Electroacupuncture plus methylcobalamin
versus methylcobalamin alone (RR Z 1.20; 95% CI:
1.03e1.40) and electroacupuncture plus thioctic acid in-
jection versus thioctic acid injection alone (RRZ 1.23; 95%
CI: 1.02e1.47) also showed a better curative effect on
global symptom improvement. Subgroup and sensitivitybias graph.
Fig. 3 Risk of bias summary graph.
16 W. Xiong et al.analyses were not performed because of the low hetero-
geneity (I2 Z 33%).
Effect on changes in nerve conduction velocity
Eight trials37e41,43e45,47 reported the outcomes of changes
in nerve conduction velocity. A total of 21 kinds of nerve
conduction velocity tests of 6 different nerves were
measured. Six trials39e41,43,45,47 indicated that electro-
acupuncture had a beneficial effect on nerve conduction
velocity, while 2 trials37,38,44 did not. The combined trial of
Li37,38 found that methylcobalamin had a better therapeu-
tic effect than electroacupuncture on motor nerve con-
duction velocity in the left median and tibial nerves, and on
motor nerve conduction velocity in the right median, tibial
and ulnar nerves. Another trial44 found that thioctic acidinjection had a better effect than electroacupuncture on
changes in motor nerve conduction velocity in the left ulnar
nerve, and on sensory nerve conduction velocity in the left
median nerve.
Adverse events
In the 2 trials42,46 that reported adverse events, no serious
untoward events occurred. The remaining trials did not
report adverse events.
Funnel plot analysis
Based on guidelines delineated in the Cochrane Handbook
of Systematic Reviews of Interventions,35 funnel plot
analysis was not conducted due to the small number of
included RCTs and the diversity of comparisons and
outcomes.
Discussion
This review could not obtain conclusive evidence about the
therapeutic effect of electroacupuncture for DPN because
of the poor methodological quality of the included trials.
There was no strong evidence to recommend electro-
acupuncture for DPN, and the positive findings should be
interpreted conservatively.
The review showed that limitations existed in both study
design and the implementation process of included RCTs.
The methodological quality of the included trials was
generally poor, which increased risk of bias of the evalua-
tion for interventions. All included trials mentioned random
allocation, however, only 5 trials37e39,44e46 provided infor-
mation regarding the method of randomization, and this
was insufficient to judge whether the randomization was
performed adequately. None of the trials adopted alloca-
tion concealment, which might have led to the in-
vestigators having prior knowledge of the allocation
sequence, and caused selection bias. Blinding method was
not reported in any included trials. Both the investigator
and the participants clearly knew which treatment was
being given, which may have introduced bias due to the
confounding factor of the placebo effect. We concede that
for trials of different forms of intervention and control
groups, the application of blinding to researchers and
subjects would have been difficult, however, blinding could
still have been used on outcome assessors. Blinding of the
outcome assessors would have been especially important
for assessing the subjective outcome of the patients’ self-
reported index. No trial provided specific information
regarding drop-outs and follow-up, and ITT analysis was not
performed to ensure authenticity of the results. The pre-
registered protocols of the included trials could not be
accessed, which prohibited us from judging whether there
was publication bias. No included trial reported that sample
calculation had been performed, such that this and the
absence of pre-registered protocols may have led to other
bias. One trial42 did not report whether the baseline char-
acteristics of the treatment and control group were com-
parable, so we deemed the risk of other bias in this RCT to
be high.
Table 4 Effect estimations of electroacupuncture for diabetic peripheral neuropathy in included trials.
Outcomes Effect estimates [95% CI] Study ID
1. Electroacupuncture vs. methylcobalamin
1.1Global symptom improvement RR 1.29 [1.14, 1.46] Li,36 Wang,40 Xue,41 Ye43
1.2 Change in NCV in each nerve MD 1.70 [0.92, 2.47]
1.2.1 Change in MNCV in common peroneal nerve MD 1.11 [0.18, 2.05] Wang,40 Ye43
1.2.2 Change in MNCV in median nerve MD 3.16 [1.00, 5.33] Xue,41 Ye43
1.2.3 Change in SNCV in median nerve MD 1.72 [0.11, 3.55] Xue,41 Ye43
1.2.4 Change in MNCV in left median nerve MD 1.60 [5.81, 2.61] Li37,38
1.2.5 Change in MNCV in right median nerve MD 2.80 [1.28, 6.88] Li37,38
1.2.6 Change in SNCV in left median nerve MD 7.50 [1.88, 13.12] Li37,38
1.2.7 Change in SNCV in right median nerve MD 1.20 [6.84, 4.44] Li37,38
1.2.8 Change in SNCV in left superficial peroneal nerve MD 5.40 [1.14, 9.66] Li37,38
1.2.9 Change in SNCV in right superficial peroneal nerve MD 2.70 [-0.88, 6.28] Li37,38
1.2.10 Change in SNCV in sural nerve MD 2.89 [1.05, 4.73] Ye43
1.2.11 Change in MNCV in tibial nerve MD 3.10 [0.69, 5.51] Xue41
1.2.12 Change in SNCV in tibial nerve MD 1.58 [0.70, 2.47] Wang,40 Xue41
1.2.13 Change in left MNCV in tibial nerve MD 3.70 [6.85, 0.55] Li37,38
1.2.14 Change in right MNCV in tibial nerve MD 1.40 [4.94, 2.14] Li37,38
1.2.15 Change in MNCV in left ulnar nerve MD 3.20 [1.08, 7.48] Li37,38
1.2.16 Change in MNCV in right ulnar nerve MD 1.20 [4.99, 2.59] Li37,38
2. Electroacupuncture vs. vitamin B
2.1 Global symptom improvement RR 1.60 [1.33, 1.94] Yang,42 Zhang47
2.2 Change in NCV in each nerve MD 3.21 [1.66, 4.77]
2.2.1 Change in MNCV in common peroneal nerve MD 3.30 [0.85, 5.75] Zhang47
2.2.2 Change in SNCV in common peroneal nerve MD 5.20 [2.79, 7.61] Zhang47
2.2.3 Change in MNCV in median nerve MD 1.30 [1.38, 3.98] Zhang47
2.2.4 Change in SNCV in median nerve MD 2.80 [0.37, 5.23] Zhang47
3. Electroacupuncture D methylcobalamin vs. methylcobalamin
3.1 Global symptom improvement RR 1.20 [1.03, 1.40] Liu,39 Zhao45
3.2 Change in NCV in each nerve MD 6.41 [4.96, 7.86]
3.2.1 Change in MNCV in common peroneal nerve MD 7.70 [6.66, 8.74] Liu39
3.2.2 Change in SNCV in common peroneal nerve MD 4.20 [3.37, 5.03] Liu39
3.2.3 Change in MNCV in median nerve MD 8.50 [7.01, 9.99] Liu39
3.2.4 Change in SNCV in median nerve MD 8.90 [7.71, 10.09] Liu39
3.2.5 Change in MNCV in left median nerve MD 5.93 [4.10, 7.76] Zhao45
3.2.6 Change in SNCV in left median nerve MD 6.42 [4.68, 8.16] Zhao45
3.2.7 Change in MNCV in right tibial nerve MD 3.12 [1.52, 4.72] Zhao45
3.2.8 Change in SNCV in right tibial nerve MD 4.63 [2.90, 6.36] Zhao45
3.2.9 Change in MNCV in left ulnar nerve MD 4.17 [2.33, 6.01] Zhao45
3.2.10 Change in SNCV in left ulnar nerve MD 8.18 [6.60, 9.76] Zhao45
4. Electroacupuncture vs. inositol
4.1 Global symptom improvement RR 1.12 [0.93, 1.35] Li36
5. Electroacupuncture vs. thioctic acid injection
5.1 Global symptom improvement RR 0.94 [0.73, 1.21] Zhao44
5.2 Change in NCV in each nerve MD 1.16 [2.14, 0.17]
5.2.1 Change in MNCV in left median nerve MD 0.99 [2.44, 0.46] Zhao44
5.2.2 Change in SNCV in left median nerve MD 2.95 [4.31, 1.59] Zhao44
5.2.3 Change in MNCV in right tibial nerve MD 0.95 [0.82, 2.72] Zhao44
5.2.4 Change in SNCV in right sural nerve MD 0.40 [1.63, 0.83] Zhao44
5.2.5 Change in MNCV in left ulnar nerve MD 1.94 [3.28, 0.60] Zhao44
5.2.6 Change in SNCV in left ulnar nerve MD 1.25 [2.61, 0.11] Zhao44
6. Electroacupuncture D thioctic acid injection vs. thioctic acid injection
6.1 Global symptom improvement RR 1.23 [1.02, 1.47] Zhao44
6.2 Change in NCV in each nerve MD 7.31 [5.50, 9.13]
6.2.1 Change in MNCV in left median nerve MD 9.79 [8.49, 11.09] Zhao44
6.2.2 Change in SNCV in left median nerve MD 8.29 [6.98, 9.60] Zhao44
6.2.3 Change in MNCV in right tibial nerve MD 4.15 [2.63, 5.67] Zhao44
(continued on next page)
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6.2.4 Change in SNCV in right sural nerve MD 5.76 [4.61, 6.91] Zhao44
6.2.5 Change in MNCV in left ulnar nerve MD 9.70 [8.32, 11.08] Zhao44
6.2.6 Change in SNCV in left ulnar nerve MD 6.09 [4.50, 7.68] Zhao44
Abbreviations: CI, confidence interval; MD, mean difference; MNCV, motor nerve conduction velocity (m/s); NA, not available; NCV,
nerve conduction velocity (m/s); RR, risk ratio; SNCV, sensory nerve conduction velocity (m/s).
Fig. 4 Forest plot of electroacupuncture versus conventional medicine for diabetic peripheral neuropathy on global symptom
improvement.
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Electroacupuncture for treatment of diabetic peripheral neuropathy 19Several problems existed in the study design of included
RCTs. Reporting of the baseline characteristics of partici-
pants was not standardized, the inclusion and exclusion
criteria were indeterminate, the age range of participants
was large, and the TCM syndrome pattern differentiation
was lacking. These factors may have resulted in an imbal-
ance between intervention and control groups such as the
imbalance of the types of syndrome patterns that were
included, reduced the validity of outcomes, and did not
reflect the uniqueness of TCM treatment based on pattern
differentiation. Future investigators should standardize
study design and the reporting of baseline characteristics,
and fully integrate TCM theory with their studies.
With regard to electroacupuncture intervention, there
were considerable differences in needling instruments
used, number of needling sessions, selection of acupoints,
depth of insertion, method of needle manipulation, and
needle retention time. None of the included trials
mentioned the practitioners’ background in accordance
with the CONSORT Statement51 and STRICTA recommen-
dation,52 such as their qualifications, professional affilia-
tion, or how long they had been practicing acupuncture.
Future studies should adopt more rigorous reporting of
interventions.
For control treatments, we regrettably found that other
control treatments have not been found except vitamin B,
inositol or alpha-lipoic acid in included trials. The phar-
maceutical drugs which are mainly used for DPN, especially
in the U.S would be an important comparison for future RCT
studies.
In terms of outcome measurement, the therapeutic ef-
fect index of each included trial was quite different, and
these were not reported in accordance with the unified
international standard such as CONSORT Statement51 and
STRICTA recommendation.52 The majority of RCTs reported
global symptom improvement and changes in nerve con-
duction velocity. However, the former was reported as a
hierarchical outcome using categories, such as “markedly
effective”, “effective” and “ineffective” and the grading
standards of included RCTs were varied and lacked unified
international standardization such as CONSORT Statement51
and STRICTA recommendation.52 For the convenience of
analysis, we summed these as binary outcomes, which
probably enlarged the uncertainty of results. Moreover, for
the changes in nerve conduction velocity, the nerves
measured in each trial were too varied to perform a meta-
analysis and draw a pooled result. No trial reported QoL or
health economic outcomes, and the reports of follow-up
results were insufficient for estimating long-term thera-
peutic effects of the treatment. Furthermore, of all the
included trials, only 2 studies42,46 reported adverse events.
This is a universal phenomenon of TCM trials performed and
published in China, where researchers often consider
treatments to be safe and overlook the importance of
safety reporting. Because of this, we cannot ascertain the
safety of electroacupuncture, and recommend compre-
hensive monitoring and reporting of adverse events are
needed in all future studies.
Our search found 1 published systematic review on
manual acupuncture for DPN53 However, manual acupunc-
ture and electroacupuncture are different types of
acupuncture therapy, and their therapeutic mechanismsand curative effects likely differ. For this reason, we did
not include that study. Our review had some limitations. We
only searched Chinese and English databases and relevant
references because of the language barrier. RCTs of elec-
troacupuncture for DPN published in other languages still
need to be assessed to more completely evaluate the
effectiveness and safety of electroacupuncture.Conclusion
We were unable to obtain conclusive evidence about the
therapeutic effect of electroacupuncture for DPN through
this review because the poor methodological quality of the
included trials reduced the reliability of our findings. More
rigorously designed, multicenter, double-blind RCTs with
reliable quality and credible conclusions are needed to
substantiate findings. Future RCTs should include informa-
tion about needling instruments, number of needling ses-
sions, selection of acupoints, depth of insertion, needle
manipulation, needle retention time, and the qualification
and experience of the practitioner. Long-term follow-up,
monitoring and reporting of adverse events are also
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